Atala Financial Inc Buys New Shares in Johnson & Johnson (NYSE:JNJ)

Atala Financial Inc acquired a new position in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,440 shares of the company’s stock, valued at approximately $353,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $35,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at $40,000. Finally, NewSquare Capital LLC boosted its stake in Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after acquiring an additional 172 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday. Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Bank of America upped their target price on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.93 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $392.28 billion, a P/E ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. The company’s 50 day moving average price is $154.60 and its two-hundred day moving average price is $156.38. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.